Clinical Trials Logo

Vulvar Squamous Cell Carcinoma clinical trials

View clinical trials related to Vulvar Squamous Cell Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02978625 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Start date: September 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.

NCT ID: NCT02140021 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

Start date: October 27, 2014
Phase: N/A
Study type: Interventional

This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer. Studying samples collected from patients in the laboratory may help doctors learn more about the human papillomavirus and how often anal cancer occurs in patients with cervix, vagina, or vulvar cancer.

NCT ID: NCT01595061 Active, not recruiting - Clinical trials for Vulvar Squamous Cell Carcinoma

Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

Start date: July 2, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well radiation therapy works when given with gemcitabine hydrochloride and cisplatin work in treating patients with squamous cell cancer of the vulva that has spread from where it started to nearby tissue or lymph nodes. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy together with gemcitabine hydrochloride and cisplatin may kill more tumor cells.

NCT ID: NCT01500512 Active, not recruiting - Clinical trials for Vulvar Squamous Cell Carcinoma

Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection

GROINSS-V
Start date: January 3, 2012
Phase:
Study type: Observational

This research trial studies patients with early-stage vulvar cancer undergoing sentinel lymph node dissection. Sentinel lymph node dissection may have fewer side effects than removing all lymph nodes. Observing patients undergoing sentinel lymph node dissection may help doctors confirm the safety of the procedure.